share_log

6-K: Voting Rights and Capital

6-K: Voting Rights and Capital

6-K:投票權和資本
美股SEC公告 ·  2024/12/02 15:30

牛牛AI助理已提取核心訊息

AstraZeneca has reported its total voting rights and capital structure as of November 30, 2024. The company's issued share capital with voting rights consists of 1,550,317,189 ordinary shares, each with a nominal value of US$0.25. No shares are currently held in Treasury.This disclosure, made in compliance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1, provides shareholders with the denominator for calculating their interest notifications in the company. The total number of voting rights remains at 1,550,317,189, which shareholders should use for their calculations regarding interest disclosure requirements.
AstraZeneca has reported its total voting rights and capital structure as of November 30, 2024. The company's issued share capital with voting rights consists of 1,550,317,189 ordinary shares, each with a nominal value of US$0.25. No shares are currently held in Treasury.This disclosure, made in compliance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1, provides shareholders with the denominator for calculating their interest notifications in the company. The total number of voting rights remains at 1,550,317,189, which shareholders should use for their calculations regarding interest disclosure requirements.
阿斯利康已報告截至2024年11月30日的總投票權和資本結構。公司發行的具有投票權的股份資本由1,550,317,189股普通股組成,每股面值爲0.25美元。目前沒有股份被持有在庫。這一披露符合英國金融行爲監管局的披露和透明度規則5.6.1,向股東提供計算其在公司利益通知時所需的分母。總投票權的數量保持在1,550,317,189,股東應使用該數進行與利益披露要求相關的計算。
阿斯利康已報告截至2024年11月30日的總投票權和資本結構。公司發行的具有投票權的股份資本由1,550,317,189股普通股組成,每股面值爲0.25美元。目前沒有股份被持有在庫。這一披露符合英國金融行爲監管局的披露和透明度規則5.6.1,向股東提供計算其在公司利益通知時所需的分母。總投票權的數量保持在1,550,317,189,股東應使用該數進行與利益披露要求相關的計算。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 359

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。